Mirtazapin Stada (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Stada, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and helps improve mood, sleep and appetite, addressing several core symptoms of depression.

GNH USA supplies Mirtazapin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. The company adheres to stringent quality standards and offers comprehensive logistics support.

Mirtazapine is indicated for major depressive disorder, a condition characterized by persistent low mood and loss of interest. - Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depressive episodes in bipolar disorder (as adjunct therapy): helps alleviate depressive phases when used alongside mood stabilizers. - Treatment‑resistant depression (as adjunct): may be added to other antidepressants to achieve response in patients who have not responded to first‑line agents.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction - Severe allergic reactions (e.g., Stevens‑Johnson syndrome)

When prescribing mirtazapine, clinicians should observe several precautions to ensure safe use. - Assess hepatic function: evaluate liver enzymes before initiating therapy. - Monitor for suicidal ideation: especially during early treatment or dose changes. - Use caution in patients with cardiovascular disease: watch for orthostatic hypotension. - Adjust dose in renal impairment: consider reduced dosing in severe renal dysfunction. - Avoid abrupt discontinuation: taper gradually to minimise withdrawal symptoms. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Mirtazapine can interact with several medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate hypertensive crisis or serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increase risk of serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): may enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma concentrations. - Antihypertensive drugs: additive hypotensive effect may occur. - Carbamazepine: can reduce mirtazapine levels, diminishing efficacy.